Emily Stearn

Emily Stearn is an award-winning journalist who joined MailOnline in January 2023. She regularly writes on the NHS, medicines regulations and women's health. Prior to joining MailOnline, Emily worked as a digital reporter at specialist healthcare publication Chemist&Druggist. She holds a degree in Journalism from Cardiff University.

Biography:  https://www.dailymail.co.uk/profile-1042/emily-stearn.html

86%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.

Bias

85%

Examples:

  • Emily Stearn is an award-winning journalist who joined MailOnline in January 2023 and regularly writes on the NHS, medicines regulations and women's health.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

95%

Examples:

  • In one article, Emily Stearn reported that GLP-1 agonists such as Wegovy and Ozempic have been linked to a lower risk of pancreatic, kidney, ovarian, colorectal, endometrial, gallbladder and stomach cancers. In another article on the same topic, she reported that those taking insulin were more than twice as likely to be diagnosed with pancreatic, colorectal, gallbladder and meningioma cancer in comparison.

Deceptions

75%

Examples:

  • In one article, Emily Stearn reported that lung cancer patient Kat Robinson was able to take tablets at home rather than get treatment in hospital. However, she still received medical attention and had her condition monitored by healthcare professionals.

Recent Articles

New Study: GLP-1 Drugs Linked to Lower Risk of Obesity-Related Cancers in Type 2 Diabetes Patients

New Study: GLP-1 Drugs Linked to Lower Risk of Obesity-Related Cancers in Type 2 Diabetes Patients

Broke On: Friday, 05 July 2024 A recent JAMA Network Open study found that GLP-1 drugs, like Ozempic and Victoza, lower the risk of obesity-related cancers in Type 2 diabetes patients. The analysis of over 1.6 million patients revealed significant reductions in gallbladder (65%) and meningioma (63%) cancer risks.
Revolutionizing Lung Cancer Detection: ctDNA Liquid Biopsies Provide Personalized Treatment Plans with Fewer Side Effects

Revolutionizing Lung Cancer Detection: ctDNA Liquid Biopsies Provide Personalized Treatment Plans with Fewer Side Effects

Broke On: Thursday, 21 March 2024 A new blood test called ctDNA liquid biopsies can detect lung cancer at an early stage and provide targeted treatments for patients. These tests look for tiny fragments of tumor DNA circulating in the bloodstream and allow doctors to make more accurate diagnoses, offer personalized treatment plans, and have fewer side effects than traditional chemotherapy.